Susquehanna Fundamental Investments LLC Acquires Shares of 88,067 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Susquehanna Fundamental Investments LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 88,067 shares of the biopharmaceutical company’s stock, valued at approximately $13,162,000. Susquehanna Fundamental Investments LLC owned approximately 0.07% of Alnylam Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Allspring Global Investments Holdings LLC raised its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Quent Capital LLC raised its holdings in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $38,000. GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $52,000. Finally, V Square Quantitative Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $52,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ALNY has been the subject of a number of research analyst reports. Needham & Company LLC boosted their price target on Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Evercore ISI boosted their price objective on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 25th. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 3rd. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Finally, TD Cowen boosted their price objective on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Eight research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.55.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $0.51 during midday trading on Friday, reaching $260.51. The company’s stock had a trading volume of 1,039,655 shares, compared to its average volume of 1,788,428. The firm has a market capitalization of $32.95 billion, a price-to-earnings ratio of -97.21 and a beta of 0.37. The firm has a 50 day moving average price of $181.10 and a two-hundred day moving average price of $169.16. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $263.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same period last year, the company posted ($1.40) earnings per share. The firm’s quarterly revenue was up 54.8% compared to the same quarter last year. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.92 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 7,093 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the sale, the executive vice president now directly owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 7,093 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total value of $1,851,273.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,168,101. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,450 shares of company stock valued at $15,287,984. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.